uniQure (NASDAQ:QURE) Director Leonard Post Sells 1,993 Shares

uniQure N.V. (NASDAQ:QURE) Director Leonard Post sold 1,993 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the sale, the director directly owned 35,494 shares in the company, valued at approximately $960,467.64. The trade was a 5.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

uniQure Stock Performance

NASDAQ:QURE opened at $27.57 on Friday. The business’s 50-day moving average price is $22.52 and its two-hundred day moving average price is $21.80. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The stock has a market cap of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, equities analysts predict that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC grew its position in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. Aberdeen Group plc grew its position in uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after acquiring an additional 738,897 shares during the last quarter. State Street Corp grew its position in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. grew its position in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares during the last quarter. Finally, Orbimed Advisors LLC grew its position in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. The Goldman Sachs Group increased their price objective on uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, April 20th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Finally, Wolfe Research assumed coverage on uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.